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Key points: 
• Platelets directly interact with and kill circulating Plasmodium parasites in malaria patients to 
help control parasitemia.  
• In vitro platelet anti-plasmodicidal activity against P. knowlesi involves platelet-cell binding 
and intracellular accumulation of PF4. 
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Abstract: Platelets are understood to assist host innate immune responses against infection, 
although direct evidence of this function in any human disease, including malaria, is unknown. 
Here we characterized platelet-erythrocyte interactions by microscopy and flow cytometry in 
malaria patients naturally infected with Plasmodium falciparum, P. vivax, P. malariae or P. 
knowlesi. Blood samples from 376 participants were collected from malaria-endemic areas of 
Papua, Indonesia, and Sabah, Malaysia. Platelets were observed binding directly with and killing 
intraerythrocytic parasites of each of the Plasmodium species studied, particularly mature stages, 
and was greatest in P. vivax patients. Platelets preferentially bound to infected more than 
uninfected erythrocytes in the bloodstream. Analysis of intraerythrocytic parasites indicated the 
frequent occurrence of platelet-associated parasite killing, characterized by the intraerythrocytic 
accumulation of platelet factor-4 and terminal deoxynucleotidyl transferase dUTP nick-end 
labeling of parasite nuclei (PF4+TUNEL+ parasites). These PF4+TUNEL+ parasites were not 
associated with measures of systemic platelet activation. Importantly, patient platelet counts, 
infected erythrocyte-platelet complexes and platelet-associated parasite killing correlated 
inversely with patient parasite loads. These relationships, taken together with the frequency of 
platelet-associated parasite killing observed amongst the different patients and Plasmodium 
species, suggest that platelets may control the growth of between 5 and 60% of circulating 
parasites. Platelet-erythrocyte complexes comprised a major proportion of the total platelet pool 
in malaria patients and may therefore contribute considerably to malarial thrombocytopenia. 
Parasite-killing was demonstrated to be platelet factor-4-mediated in P. knowlesi culture. 
Collectively, our results indicate that platelets directly contribute to innate control of 
Plasmodium infection in human malaria. 
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Introduction 
Platelets are the second most abundant cell of the circulation after red blood cells (RBC) and the 
principle regulators of hemostasis. Platelets can also integrate host immune responses through 
production of immunomodulatory molecules and via cell-to-cell interactions with white blood 
cells (WBC), and may have host-protective roles in infectious disease.1 Platelets are an abundant 
source of antimicrobial molecules2,3, have broad-spectrum pathogen killing activities4-9 and are 
required for host-mediated pathogen control and host survival in some infectious disease 
models.10-13 Clinically, low platelet counts are often associated with a poor prognosis and 
increased risk of infection.14-16 However, to date direct evidence that platelets contribute to host 
protection in any human infectious disease is lacking. 
Malaria kills over 400 000 people each year.17 While most deaths are caused by Plasmodium 
falciparum, all Plasmodium species can cause severe and fatal infection.18-21 Malaria 
pathogenesis is driven primarily by parasite biomass22-24 and modulated by host innate and 
adaptive immune responses.25,26 Thrombocytopenia is common in all malarias and is a risk factor 
for mortality in African children with falciparum malaria27, Southeast Asian adults and children 
with falciparum and vivax malaria28, and adults with knowlesi malaria.21 However, the 
mechanisms leading to thrombocytopenia are not fully understood and its subsequent effects on 
parasite biomass, disease control or progression has yet to be quantified for any of the human 
Plasmodium species. 
Indirect evidence from separate sources suggests that platelets may contribute to the host 
protection in malaria. This includes observations of human platelets directly binding to and 
killing P. falciparum-infected RBC (iRBC) in culture, and reduced survival in Plasmodium-
infected mice depleted of platelets.12,13,29-31 A mechanism for the direct killing of Plasmodium 
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involves platelet factor-4 (PF4), an abundant antimicrobial protein secreted by platelets, that, 
upon entering the cell via the Duffy-antigen – a chemokine receptor expressed by RBC30 – kills 
P. falciparum parasites by selectively lyzing the parasite digestive vacuole.29 However, a recent 
study did not reproduce the parasite killing effect of platelets in P. chabaudi-infected mice or P. 
falciparum-iRBC32, showing the difficulties in using in vitro and in vivo disease models to study 
these phenomena33, and highlighting the need for additional research in people with malaria.34  
No clinical studies have addressed the role of platelets in killing P. falciparum parasites across 
the spectrum of clinical disease, nor their role in protection and pathogenesis in human malaria 
from non-falciparum Plasmodium species. Here we characterized cell-to-cell platelet interactions 
in patients naturally infected with P. falciparum, P. vivax, P. malariae or P. knowlesi, and 
examined relationships between platelet-associated parasite killing and parasite biomass. We 
also demonstrate the mechanism by which human platelets can kill P. knowlesi, a second 
culturable human Plasmodium species. 
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Methods 
Study participants 
In Papua, malaria patients attending the Mitra Masyarakat Hospital in Timika were enrolled 
between 2014-2016. This lowland forest region has perennial transmission of P. falciparum, P. 
vivax and P. malariae. In Sabah, patients were enrolled between 2012-2016 from 3 district 
hospitals in Kudat Division as part of concurrent prospective clinical studies.35 Sabah is an area 
of low malaria transmission, which during this period was co-endemic for P. falciparum, P. 
vivax, and the zoonotic parasite, P. knowlesi. 
Criteria for enrolment in both cohorts included: a blood film positive by microscopy for any 
Plasmodium species, including mixed infections in Papua, fever or history of fever in the last 48 
h, no major concurrent illness or co-morbidity, and no prior antimalarial therapy in the preceding 
24 h. Patients were excluded if pregnant or lactating. In Papua patients aged <16 or >60 years or 
with a hemoglobin concentration 7 g/dL were also excluded. Severe malaria was defined 
according to WHO 2014 research criteria.20 Hospitalization was at the discretion of the treating 
clinician in Papua and was mandatory in all malaria patients in Sabah. All malaria patients were 
treated according to local guidelines as described previously.20,36-38  Controls were selected from 
visitors or relatives of malaria patients, with no fever or history of fever in the preceding 14 d 
and with a blood film negative for malaria parasites. 
Details of blood collection and analysis procedures are described in Supplementary Materials.  
 
Platelet binding to iRBC and uRBC 
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Blood samples were analyzed by flow cytometry to measure platelet-bound iRBC or uninfected 
RBC (uRBC), and expressed as frequencies and absolute numbers. In Papua, assays were 
performed on fresh samples and in Sabah on fixed blood (Cytofix™, BD Biosciences). 
Fluorescent antibody panels comprised anti-CD45 (white cell exclusion marker), anti-CD41 or 
CD42b (platelet marker), anti-CD235ab (RBC marker), and either Hoechst 33342 or DRAQ-5 
(parasite nuclear marker). The gating strategy for measuring platelet-iRBC/uRBC complexes in 
Papua is illustrated in Fig. 1B and in Sabah in Fig. S1A. Refer to Supplementary Materials for 
details of the staining materials and procedures. 
 
Platelet-associated parasite killing 
Immunofluorescent microscopy of Cytofix™-treated blood was used to quantify platelet-
associated parasite killing, based on a terminal deoxynucleotidyl transferase dUTP nick-end 
labeling (TUNEL) assay described elsewhere30 that labels degraded or sheared DNA, an 
indication of apoptosis or necrosis. Platelets and intraerythrocytic localization of PF4 were 
detected with an anti-human PF4 Ab (Abcam, UK) and intraerythrocytic Plasmodium DNA was 
identified using DAPI. Only high parasitemia samples (>5000 parasites/µL) were analyzed and 
the number of parasites counted per sample recorded. In a subset of patients, iRBC were 
distinguished into rings (DAPI+ without parasite pigment) or mature stages (DAPI+ with parasite 
pigment) by immunofluorescence, and the proportion of stages confirmed with Giemsa-stained 
blood smears performed in parallel. Refer to Supplementary Materials for more detail. 
 
Platelet activation 
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In Papua, platelet activation markers including platelet PAC-1 binding (recognizing the 
glycoprotein IIb/IIIa complex of activated platelets), P-selectin (CD62P) surface expression, and 
platelet-monocyte and platelet-neutrophil aggregate formation, were measured using two flow 
cytometry panels. Plasma PF4 concentrations were measured by ELISA. In Sabah, platelet-WBC 
aggregates were determined from the RBC-binding panel. The platelet activation gating 
strategies are illustrated in Fig. S1, B and C. Refer to Supplementary Materials for details of the 
staining and analysis procedures. 
 
In vitro parasite and platelet experiments 
P. knowlesi and P. falciparum were cultured in 2.5% hematocrit O+ human RBC as described 
elsewhere.39,40 Platelets were purified from freshly collected human blood as described 
previously.12 Refer to Supplementary Materials for details of the culture conditions and platelet 
preparation.  
Platelet count and quiescence were determined using an ADVIA 2120i hematology analyzer 
(Siemens, Australia). Platelet activation capacity was tested by treating platelets with 1 U/mL of 
human thrombin for 10 min, then measuring PAC-1 binding and P-selectin surface expression by 
flow cytometry. All platelet preparations in this study (8 preparations from six donors) satisfied 
the criteria for quiescence (mean platelet volume <9 fL and mean platelet component >23 g/dL) 
and activation capacity (>1000-fold and >250-fold increase in PAC-1 and CD62P MFI, 
respectively, compared to untreated rested platelets) (Fig. S4). 
For the parasite-platelet co-culture experiments, P. falciparum parasites were synchronized for 
ring stages the day before experiments using 5% (w/v) D-sorbitol.41 Late-stage P. knowlesi and 
P. falciparum trophozoites were purified on the day of experiment using 70% Percoll® gradient 
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centrifugation (3500 RPM without brake for 10 min) and washed twice with complete culture 
medium (CCM). Parasitemia was adjusted to 0.5% at 2% hematocrit and platelets added; equal 
volumes of Tyrode’s buffer were added to untreated controls. In some experiments before adding 
to the parasites, recombinant human PF4 (Peprotech, US) and platelet lysates were incubated 
with 0.5 mg/mL of preservative-free rabbit anti-human PF4 Ab (Abcam, UK) or preservative-
free rabbit serum (Novus Biologicals, US) for 15 min at 4°C. For transwell experiments, 
parasites were separated from 50 million platelets/mL, platelet lysate or 0.5 M PF4 using 
transwell inserts with 0.2 m pore size (AnoporeTM membrane, Nalge Nunc International, 
Denmark). The well inserts were pre-soaked with CCM prior to use. P. knowlesi was harvested 
after 24 h, and P. falciparum after 48 h culture with platelets, lysate or protein. Giemsa-stained 
thin smears were prepared, and 1000 RBC were counted per slide at 1000x magnification. 
Percent parasite growth was calculated using the formula below. 
% Parasite Growth = [(treatment parasitemia − initial parasitemia) ÷ (untreated parasitemia − 
initial parasitemia)] x 100 
Platelet binding to parasites was determined in 24 h cultures containing 2% asynchronous 
parasites and 60 million platelets/mL. Harvested co-cultures were fixed in diluted CytofixTM 
(Biosciences, Australia) for at least 24 h and stored at 4°C. For flow cytometry quantitation, 
fixed cells were washed once with 1% (w/v) BSA/PBS, then stained with mouse anti-human 
CD42b conjugated to phycoerythrin and mouse anti-human CD235ab conjugated to 
allophycocyanin for 20 min at 4°C, followed by 5 µg/mL Hoechst 33342 for 5 min at 4°C. 
Fluorescence signals were measured using the LSR Fortessa (BD Biosciences). At least 100 000 
events were collected per sample. 
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Statistics 
The Mann-Whitney test or the Kruskal-Wallis test followed by Dunn’s multiple comparisons 
was used for between-group comparisons of clinical data. The Wilcoxon matched-pairs signed 
rank test was applied to paired datasets. One-way ANOVA with Sidak’s multiple comparisons 
was used for in vitro data. Associations between two variables were assessed using Spearman 
correlation. Bonferroni corrections to P-values were applied where appropriate. Data were log 
transformed for multivariate comparisons. All statistical analyses were performed using 
GraphPad Prism 7 (GraphPad Software, La Jolla, CA) or Stata 14 (StataCorp, Texas, US).  
 
Study approval 
The study was approved by the Human Research Ethics Committees of Gadjah Mada University, 
Indonesia (Papua), the Malaysian Ministry of Health (Sabah), Menzies School of Health 
Research, Australia (Papua and Sabah), the Macquarie University and the Australian National 
University. Written informed consent was obtained from all participants. 
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Results 
Study participants 
Separate cohorts of malaria patients and healthy controls were enrolled in Papua, Indonesia 
(n=143), and Sabah, Malaysia (n=233). Patients were categorized according to Plasmodium 
species, and baseline characteristics, including parasitemia, platelet counts and disease severity 
presented (Tables 1 and 2). The majority of malaria patients at each site had non-severe malaria, 
92% in Papua and 97% in Sabah. Relative to controls, platelet counts were significantly lower in 
malaria from all Plasmodium species at both study sites and correlated inversely with 
parasitemia in the P. vivax groups (Papua, r=-0.37, p=0.022, n=38; Sabah, r=-0.36, p=0.0008, 
n=84) and with histidine-rich protein-2 (HRP2) in falciparum malaria in Papua (r=-0.45, 
p=0.0007, n=54). 
 
Platelet-iRBC and platelet-uRBC complexes are formed in the circulation of malaria 
patients 
Examination of patient thin blood smears revealed platelet binding to both iRBC and uRBC. 
Platelets were bound to all asexual parasite stages in each of the Plasmodium species, with 
evidence of platelet aggregates surrounding P. vivax-iRBC (Fig. 1A). Characteristic features of 
dying parasites within platelet-bound iRBC were observed, including spread of parasite pigment 
suggesting dissolution of the digestive vacuole. 
Flow cytometry was used to quantify the proportions of uRBC and iRBC that were each bound 
to platelets, hereafter platelet-uRBC and platelet-iRBC complexes (Figs. 1B and S1A). 
Proportions of platelet-uRBC were similar amongst all the patient groups (median range: 0.10% 
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– 0.19%) and were significantly lower than the controls (0.28% and 0.42%; Fig. 1, Ci and Cii, 
respectively). In contrast, greater proportions of platelet-iRBC were observed in all the patient 
groups (Fig. 1, Di and Dii, and Table S1). The greatest proportions were observed in P. knowlesi 
patients (median 18.1%), which was significantly higher than in Sabah P. falciparum patients 
(median 6.3%; p=0.002, Table S1); Overall complex magnitudes were lower in the Papua than 
the Sabah groups, which may be attributable to differences in sample preparation and staining. 
However, for all groups platelet-iRBC complexes were significantly greater than platelet-uRBC 
complexes. Compared as a ratio, the proportions of platelet-iRBC complexes were between eight 
and almost 100-fold greater than platelet-uRBC complexes (Table S1). We also separately 
analyzed the subgroup of 28 Sabah patients with P. vivax or P. knowlesi malaria who were 
children aged 12 or younger (Table 2); similar proportions of platelet-iRBC/uRBC complexes to 
adults, and significantly greater frequencies of platelet-iRBC versus platelet-uRBC were 
observed in these groups (Fig. S3, A–C). 
Using the proportions of the complexes and the respective RBC count in each individual, we 
calculated concentrations of platelet-RBC complexes (iRBC and uRBC combined). The medians 
ranged between 3,100 and 13,600/µL blood (Table 3). Compared to respective circulating levels 
of free platelets (i.e. free platelet:platelet-RBC complex ratio; Table 3), the complexes comprise 
a substantial proportion of the total platelet pool. For example, in P. knowlesi-infected patients, 
on average, one complex was predicted to exist for every 7 non-complexed platelets. The highest 
ratio, in P. malariae, predicted one complex for every 19 platelets (Table 3). By comparison, 
free platelet:platelet-WBC ratios were much higher ( 118), indicating these complexes were 
only a minor component of the platelet pool (Table 3).  
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Correlative analyses revealed inverse relationships between platelet-iRBC complexes and 
parasitemia; these were significant in malaria from each species, except P. malariae (Fig. 1, Ei, 
Eii and Fig. S2A). After adjusting for platelet count, these relationships remained significant for 
P. vivax and P. knowlesi (both p<0.0001). No significant relationships were observed between 
parasitemia and platelet-uRBC complexes. There was no consistent relationship between 
complexes and hemoglobin levels.  
Taken together, these data show that platelets bind and form stable complexes with RBC, with a 
greater preference for iRBC than uRBC. The frequencies of these complexes in the circulation of 
patients and controls are substantial and compared to free platelets comprise a relatively large 
proportion of the total platelet pool. In addition, the proportions of platelet-iRBC complexes are 
higher in patients with low levels of parasites, and lower in patients with high parasite burden.  
 
Platelets directly kill parasites in the circulation of malaria patients 
We conducted TUNEL and PF4 immunostaining on patient blood to detect and quantify the 
frequencies of dead intraerythrocytic parasites and the co-occurrence of PF4 accumulation within 
the iRBC. With these methods, iRBC containing PF4 and TUNEL labeling (PF4+TUNEL+) are 
indicative of direct platelet contact with the cell (by uptake of platelet-produced PF4) and 
consequent PF4-mediated killing of the parasite.29,30 We observed PF4+TUNEL+ iRBC in all 
Plasmodium species in both patient cohorts (Fig. 2A). Quantification of these observations 
showed substantial variances in the proportions of PF4+TUNEL+ iRBC, although the medians 
calculated for each species were similar, except for P. vivax, which was significantly greater in 
both Papua and Sabah compared to the other species (Fig. 2B and Table 4). Notably, PF4 was 
present in more than half of the TUNEL+ (dead) parasites; in Papua, a median of 96% of 
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TUNEL+ P. vivax-iRBC contained PF4, which was significantly greater than the 52% median 
observed in P. falciparum (p<0.0001) and 69% median in P. malariae (p=0.051) (Fig. 2C). No 
PF4 staining or TUNEL labeling was observed in enriched suspensions of uninfected 
reticulocytes. The proportion of PF4+TUNEL+ iRBC correlated inversely with parasitemia in 
Papuan patients infected with P. vivax (r=-0.42, p=0.020) and P. falciparum (r=-0.36, p=0.010); 
no significant relationships were observed in the other cohort groups, in which fewer samples 
were examined (Fig. 2D and Fig S2B).  
We compared PF4+TUNEL+ frequencies in young (ring) versus mature (trophozoite and 
schizont) asexual stage parasites (Fig. 2E and Table 4). In the Papuan P. vivax samples, 
PF4+TUNEL+ mature-stage parasites outnumbered ring-stages almost ten times (63.6% vs 6.4%; 
p<0.0001); there was a similar significant difference in P. malariae (6.3% vs 0%; p=0.007), but 
not in P. knowlesi (14.9% vs 10.8%; p=0.354). Only ring-stage parasites were observed in the P. 
falciparum samples, consistent with the ability of mature stages to sequester in tissues. There 
were no significant differences in the proportions of PF4+TUNEL+ rings between patient location 
or parasite species (Fig. 2F). All ring-stage parasites (i.e. TUNEL+ and TUNEL-) were also 
categorized according to PF4 staining; the greatest proportions were observed in Papuan P. vivax 
samples (median 43.8%), which was significantly greater than in P. falciparum or P. malariae 
(median 12.0% and 9.1%, respectively; Fig. 2G).  
Collectively these data show that, irrespective of species, a substantial proportion of Plasmodium 
accumulate platelet-derived PF4 and undergo intraerythrocytic death, most likely as a 
consequence of the known cytotoxic actions of PF4.  
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Platelet-derived PF4 accumulation in iRBC and parasite killing are not associated with 
systemic platelet activation 
We observed that not all PF4-stained parasites were bound by platelets (Range 0-25%) and some 
platelet-bound cells were not stained for PF4 (Range 0-5.9%; Table S2). We determined if 
systemic platelet activation contributes to absorption of plasma PF4 into the iRBC. None of our 
markers for platelet activation, including plasma PF4 concentrations, platelet surface expression 
of CD62P (P-selectin) and PAC-1 (activated GPIIb/IIIa) on circulating platelets, were 
significantly elevated in any of the patient groups (Table S3). In addition, no relationships were 
observed that supported a role for systemic platelet activation in the iRBC accumulation of PF4 
(Table S4).  
 
Cultured P. knowlesi and P. falciparum are sensitive to human platelets and PF4 
In vitro platelet killing of P. falciparum has been demonstrated previously12,29-31 but not for other 
human Plasmodium species. We therefore co-cultured P. knowlesi with or without different 
concentrations of washed and rested human platelets and measured effects on parasite growth 
over 24 h. We observed a significant and platelet concentration-dependent reduction in parasite 
growth, maximal at 75 million platelets/mL (~60% reduction) (Fig. 3A). Implementation of 
platelet-to-iRBC ratios and parasitemias comparable to clinical settings, and strict control of 
platelet quality (Fig. S4) were critical components of our experimental system. A similar 
significant growth inhibition effect was also observed in P. falciparum cultures treated with the 
same platelet preparations (Fig. 3B). P. knowlesi was sensitive to recombinant human PF4 (IC50 
~ 0.5 µM), and to treatment with platelet lysates, which was blocked by inclusion of anti-PF4 
antibodies (Fig. 3, C and D). Platelet inhibition of parasite growth was prevented when platelets 
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and P. knowlesi-iRBC were physically separated in co-cultures using cell-impermeable 
transwells, but remained sensitive to platelet lysate and PF4 (Fig. 3E), indicating that direct 
platelet-cell contact and platelet-derived PF4 are responsible for the cytotoxic effects. 
Platelets were observed physically bound to P. knowlesi-iRBC (Fig. 3F). The frequency of 
platelet-iRBC complexes was twice of platelet-uRBC complexes in both P. knowlesi and P. 
falciparum after 24 h incubation with platelets and was significant for P. knowlesi (p<0.05; Fig. 
3G). Platelet-treated P. knowlesi cultures contained significantly greater proportions of TUNEL+ 
iRBC; the majority of these iRBC were also PF4+ (Fig. 3, H and I). PF4 was not detected in 
untreated iRBC (Fig. 3H). Collectively, human platelets can kill both P. falciparum and P. 
knowlesi asexual blood-stage parasites under well-defined culture conditions. The killing 
mechanism requires platelet-cell contact and PF4; intraerythrocytic PF4 is cytotoxic to P. 
knowlesi. 
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Discussion 
Here we demonstrate for the first time in humans that platelets can directly kill a microbial 
pathogen, erythrocytic stage Plasmodium. Platelets were observed bound to Plasmodium-iRBC 
of all four of the major species that cause human disease, P. falciparum, P. vivax, P. malariae 
and P. knowlesi. Platelet binding to uRBC was also observed, although the proportions of these 
were significantly lower than platelet-iRBC complexes. In addition, the proportions of platelet-
iRBC complexes were inversely related to parasite burden, suggesting a potential cause and 
effect relationship between cell-cell binding and parasite growth. We observed frequent 
intracellular accumulation of PF4 in these iRBC and death of the intraerythrocytic parasites. 
Further evidence of platelet’s cytotoxic mechanism of action against parasites was obtained 
using cultures of P. knowlesi and P. falciparum. The frequent occurrence of platelet-associated 
killing of parasites in the periphery of malaria patients, and its inverse correlation with parasite 
load, significant at least for P. falciparum and P. vivax, suggests the importance of platelets in 
the host control of parasites.  Collectively, our data predict that platelets may kill as many as 5-
20% of circulating blood-stage Plasmodium in clinical malaria, and in P. vivax this may be as 
high as 60%. 
We have previously proposed a mechanism of PF4 accumulation and parasite killing involving 
direct platelet-iRBC contact followed by local release of PF4 and uptake into the parasite via the 
Duffy-antigen.30 Here, our in vitro studies using transwell filters to separate platelets and P. 
knowlesi parasites demonstrated that direct platelet-cell contact is necessary for parasite killing, 
which confirms previous studies.31 Our cumulative in vitro data contrast with recent findings 
reported by Gramaglia and colleagues32, who found no parasite growth inhibition by platelets in 
P. falciparum cultures. We predict this is due to differences in experimental design, noting 
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especially that in vitro parasite killing by platelets is only observed in cultures containing 
physiologically relevant proportions of parasite-infected cells (<1%, in this study and previously 
12,31). The aforementioned study also did not observe changes in parasite growth rates when 
platelet levels were altered in Plasmodium-infected mice, or evidence that platelets were required 
for survival, which conflicts the findings of others.12,13 This could be due to differences in the 
Plasmodium strains used amongst the studies, which can affect parasite virulence, growth and 
sequestration, and host response characteristics. In addition, recognizing the definitive parasite 
killing activity of platelets in the circulation requires distinguishing dead parasites from healthy 
parasites, which are greatest in platelet sufficient mice12 and in parasitized cells that contain 
platelet-derived PF4 (this study and 30). In the patient studies we also considered, and excluded, 
the possibility that PF4 is absorbed by circulating parasites from the plasma. Systemic platelet 
activation was negligible and plasma PF4 concentrations were approximately 1000-fold lower 
than in vitro concentrations required for Plasmodium killing. We also observed substantially 
higher frequencies of PF4 accumulation in mature-stage P. vivax-iRBC and greater rates of 
parasite death. Accumulation may be determined by the higher Duffy-antigen levels expressed 
on reticulocytes42-44, for which P. vivax has an exclusive tropism.45 While circulating P. vivax 
parasitemia is intrinsically limited by the number of circulating reticulocytes, we speculate that 
the greater degree of platelet-associated killing observed in P. vivax infection may be a 
substantial additional contributor to the lower parasitemia generally observed in these patients 
compared to P. falciparum.18,46,47 
Platelet cytoadherence to the endothelium and WBC are well-established pathological drivers of 
vascular and inflammatory diseases. However, the occurrence and consequences of platelets 
interacting with RBC in any disease setting have been under-reported.48-50 Our unique ability to 
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systematically characterize platelet-RBC interactions revealed that platelets have a greater 
capacity to bind Plasmodium-iRBC versus uRBC. This may be partly determined by parasite-
expressed proteins present on the RBC surface, such as the P. falciparum cell adhesion molecule 
PfEMP1 shown previously to mediate platelet binding through CD36.51 Platelet binding to uRBC 
may be mediated through erythroid-expressed ICAM-4 and platelet GPIIb/IIIa.52 The identities 
and roles of other RBC and platelet molecules involved in platelet-RBC binding, especially in 
the other Plasmodium species, remain to be determined.   
Platelet-RBC complexes may have a role in malaria-induced thrombocytopenia, which has been 
reported in many other clinical studies53-55, and was also evident in our patient groups. The 
underlying causes of thrombocytopenia have been variously attributed to systemic platelet 
activation, immune-mediated clearance and vascular pooling.56-61 Platelets complexed with RBC 
are not recognized by hematological analyzers, thus complex formation would lead to an 
apparent platelet loss. The high frequencies of these complexes relative to free platelets in our 
patients suggest they comprise a substantial proportion of the total platelet pool. If there is an 
accelerated turnover of these complexes, this would further enhance the contribution of 
complexes to platelet loss. Interestingly, host mechanisms that remove diseased and damaged 
circulating cells such as the spleen are upregulated in malaria62; the lifetime of platelet-RBC 
complexes in the circulation remains unknown. Further supporting this hypothesis, platelet-RBC 
complexes were greatest in our knowlesi malaria patients and this species causes the highest 
frequency of thrombocytopenia.35,53  
Platelet activation and binding is considered a key mechanism in enabling sequestration of P. 
falciparum-iRBC to microvasculature and platelet-mediated iRBC sequestration is associated 
with fatal outcome in cerebral malaria studies.63-66 Our data in predominantly non-severe P. 
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falciparum, P. vivax, and P. malariae indicated negligible systemic platelet activation. Systemic 
platelet activation in severe and non-severe falciparum malaria were comparable, however, 
numbers were small and we cannot exclude greater systemic platelet activation in human severe 
malaria67,68, nor can we exclude tissue platelet activation not detected by the circulating measures 
used in this study.   
Overall, our study demonstrates the direct pathogen-killing actions and host protective roles of 
platelets during human malarial infection. Given platelets show broad-spectrum anti-microbial 
activity, and the risks of infection associated with thrombocytopenia and platelet disorders are 
elevated, a general role for platelets in the innate host defence against microbial infection should 
be considered. 
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Figure Legends 
 
Fig. 1. Platelet binding in clinical malaria blood samples. A) Photos of platelet-bound iRBC 
from patient Giemsa smears (black arrowhead = platelet). Images were taken at 1000x 
magnification using a Samsung Note-3 camera attached to an Olympus CX31 microscope. Scale 
bar = 5 µm. B) Representative flow cytometry gating strategy to measure platelet binding in a P. 
falciparum patient and healthy control. C) Frequency of platelet-bound uRBC by flow cytometry 
in malaria patients compared to controls in samples from Ci) Papua (controls n=17, Pf n=23, Pv 
n=26, Pm n=9, mixed n=7) and Cii) Sabah (controls n=28, Pf n=14, Pv n=85, Pk n=106) 
(Kruskal-Wallis, *significantly different to all other groups). D) Frequency of platelet-bound 
iRBC and uRBC by flow cytometry in samples from Di) Papua (n as per Ci) and Dii) Sabah (n as 
per Cii) (Wilcoxon test). E) Inverse correlation of platelet-bound iRBC with parasitemia in 
samples from Ei) Papua and Eii) Sabah (Spearman). Scatterplots indicate median ± interquartile 
range for each group. Parasitemia values are log transformed. Data presented in Table S1. 
Abbreviations: Pf, P. falciparum; Pv, P. vivax; Pm, P. malariae; Pk, P. knowlesi. 
 
Fig. 2. PF4-associated parasite killing in clinical malaria samples. A) Representative 
immunofluorescent images from Pf, Pv, Pk and Pm patient blood smears illustrating PF4-
associated parasite killing (PF4+TUNEL+ iRBC). Scale bars = 5 µm. Arrows and arrowheads 
indicate platelets and parasites, respectively. Images were taken at 630x magnification on an 
Axio Scope A1 fluorescent microscope coupled to an Axiocam ICm-1 CCD camera, or an Axio 
Observer inverted fluorescence microscope coupled to an Axiocam 503 monochrome camera. 
ZEN 2 software was used for image acquisition and processing (all from Carl Zeiss, Germany).  
B) Percentage of PF4+TUNEL+ parasites in clinical samples with Pf (Papua n=50, Sabah n=14), 
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Pv (Papua n=32, Sabah n=13), Pm (n=11), Pk (n=15) and mixed species infection (n=6). C) 
Comparison of intraerythrocytic PF4 (PF4+) parasites as a percentage of dying (TUNEL+) 
parasites in Pf, Pv, Pm, Pk and mixed species infection from Papua and Sabah (n as per panel B). 
D) Inverse correlation of PF4+TUNEL+ iRBC with parasitemia in Pf and Pv clinical samples 
(Spearman). E) Proportions of PF4+TUNEL+ rings versus mature stages in Pv (rings n=15, 
mature n=16), Pm (rings n=6, mature n=9) and Pk (rings n=8, mature n=5). F) Proportions of 
rings that were PF4+TUNEL+ and G) PF4+ in Pf (Papua n=50, Sabah n=14), Pv (n=15), Pm 
(n=6) and Pk clinical samples (n=8). Scatterplots indicate median ± interquartile range for each 
group. Parasitemia values are log transformed. Kruskal-Wallis or Mann-Whitney test used for 
statistical comparisons. Data presented in Table 4. Abbreviations: Pf, P. falciparum; Pv, P. 
vivax; Pm, P. malariae; Pk, P. knowlesi.    
 
Fig. 3. In vitro cultures of P. knowlesi are sensitive to platelets and PF4. The growth of A) P. 
knowlesi (n=4) and B) P. falciparum (n=3) treated with different platelet concentrations or 
Tyrodes buffer for 48 h. C) The growth of P. knowlesi treated with platelet lysate, with and 
without anti-PF4 antibodies or IgG isotype control (n=2). D) P. knowlesi PF4 dose response 
curve (n=2). E) The growth of P. knowlesi treated with platelets (60 million/mL), platelet lysate 
or PF4 (0.5 µM), and co-cultured in standard wells or Transwells (n=2). F) Micrographs showing 
platelets bound to uninfected and P. knowlesi-infected cells. G) Percent platelet binding to 
uninfected, P. knowlesi (n=4) or P. falciparum iRBC (n=3), determined by flow cytometry. H) 
Percent TUNEL-labelled (TUNEL+) P. knowlesi parasites co-stained for PF4 (PF4+) or not PF4-
stained (PF4-) (n=3). I) Micrographs showing a PF4+TUNEL+ P. knowlesi infected cell after 
platelet treatment. Scale bars = 5 µm. Images were taken at 630x magnification on an Axio 
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Observer inverted fluorescence microscope coupled to an Axiocam 503 monochrome camera 
with ZEN 2 software (Carl Zeiss, Germany). Bars indicate means of replicate data points. 
Kruskal-Wallis test or one-way ANOVA used for statistical comparisons: *p<0.05 and 
**p<0.01. Abbreviation: DIC, differential interference contrast. 
Figure 1
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Figure 3
